An open letter signed by key figures in UK biopharma, calls on industry leaders, HR and recruitment organizations to increase diversity in sector boardrooms and C-suites, by facilitating the path of women and minorities to the top. They note that biopharma lags behind other industries and that all-male boards are associated with under-performance compared with mixed-gender boards of recently floated firms.
A letter calling for action to increase diversity in biopharma sector boardrooms and C-Suites throws down the gauntlet to UK biotech industry managers, calling particularly on male leaders to help women progress to the highest levels.
The letter, signed by key people from the biopharma sector including Annalisa Jenkins, CEO of Dimension Therapeutics Inc. and...
Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.
Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.
As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?
Swiss major confident that new oncology drugs will fill revenue gap.
With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.
After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.
Swiss major confident that new oncology drugs will fill revenue gap.
